Elizabeth Voss

13 Aug: LSO RESPONDS TO THE PMPRB’S JUNE 2020 DRAFT GUIDELINES CONSULTATION

Life Sciences Ontario remains deeply concerned about the federal government’s patented medicine price controls and their potential to undermine the life sciences sector’s efforts to support the health and well-being of Canadians and the economy, particularly during the unprecedented COVID-19 pandemic. There is a growing body of evidence showing that…

02 Jun: LSO supports delay of federal drug pricing rules implementation

Life Sciences Ontario applauds the federal government’s recent decision to delay the implementation of the Patented Medicines Regulations to January 1, 2021 as part of the response to the COVID-19 crisis. This measure will help the Canadian life sciences sector remain unwaveringly focused on developing vaccines, treatments, and other tools to fight…

26 Mar: Ontario Fiscal Update 2020

March 2020 Economic and Fiscal Update As a result of the response to the COVID-19 outbreak, the government is planning for a deficit of $20.5 billion in 2020-21. The government will table a budget no later than November 15, 2020. Summary: The government proposes to retroactively raise the EHT exemption…

10 Jan: MEMBER ANNOUNCEMENT: adMare BioInnovations and Accel-Rx Unite to Advance the Canadian Life Sciences Sector

Vancouver, Canada – January 9, 2020: With a shared vision to be a catalyst for Canadian life sciences leading the world, adMare BioInnovations, Canada’s Global Life Sciences Venture (adMare), and Accel-Rx, Canada’s Health Sciences Accelerator (Accel-Rx), announced today they are bringing their respective capabilities and resources together under adMare to…

09 Dec: New data demonstrates that federal price controls on medicines are already driving decisions to delay or not launch new therapies in Canada, reduce clinical trial investments and stall compassionate access and patient support programs

Life Sciences Ontario commissioned Research Etc., an established Toronto research firm, to conduct a survey of pharmaceutical and other life sciences leaders on the Canadian price regulations policy environment. Preliminary results of the survey are now available, drawing on 23 responses from unique organizations representing Canadian and global pharma leaders….